Page 62 - Read Online

Toner M, Maheswaran S, Haber DA. Androgen receptor Mol Diagn Ther 2014;18:389-402.
signalling in circulating tumor cells as a marker of 82. Romiti A, Raffa S, Di Rocco R, Roberto M, Milano A,
hormonally responsive prostate cancer. Cancer Discov Zullo A, Leone L, Ranieri D, Mazzetta F, Medda E, Sarcina I,
2012;2:995-1003. Barucca V, D’Antonio C, Durante V, Ferri M, Torrisi MR,
70. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, Marchetti P. Circulating tumor cells count predicts survival
A’Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, in colorectal cancer patients. J Gastrointestin Liver Dis
Oommen NB, Hawche G, Jameson C, Thompson E, 2014;23:279-84.
Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, 83. van Dalum G, Stam GJ, Scholten LF, Mastboom WJ, Vermes I,
Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS. Tibbe AG, De Groot MR, Terstappen LW. Importance of
Characterization of ERG, AR and PTEN gene status in circulating tumor cells in newly diagnosed colorectal cancer.
circulating tumor cells from patients with castration-resistant Int J Oncol 2015;46:1361-8.
prostate cancer. Cancer Res 2009;69:2912-8. 84. Barbazán J, Alonso-Alconada L, Muinelo-Romay L, Vieito M,
71. Giesing M, Suchy B, Driesel G, Molitor D. Clinical utility Abalo A, Alonso-Nocelo M, Candamio S, Gallardo E,
of antioxidant gene expression levels in circulating cancer Fernández B, Abdulkader I, de Los Ángeles Casares M,
cell clusters for the detection of prostate cancer in patients Gómez-Tato A, López-López R, Abal M. Molecular
with prostate-specifi c antigen levels of 4-10 ng/mL and characterization of circulating tumor cells in human metastatic
disease prognostication after radical prostatectomy. BJU Int colorectal cancer. PLoS One 2012;7:e40476.
2010;105:1000-10. 85. Loveday RL, Titu L, Beral D, Jordison VL, Monson JR,
72. Hu B, Rochefort H, Goldkorn A. Circulating tumor cells in Greenman J. Telomerase activity in circulating colorectal
prostate cancer. Cancers 2013;5:1676-90. tumour cells. Cancer Ther 2004;2:115-20.
73. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, 86. Molnar B, Ladanyi A, Tanko L, Sréter L, Tulassay Z.
Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cell clusters in the peripheral blood of
Circulating tumor cells predict survival benefi t from treatment colorectal cancer patients. Clin Cancer Res 2001;7:4080-5.
in metastatic castration-resistant prostate cancer. Clin Cancer 87. Bork U, Rahbari NN, Schölch S, Reissfelder C, Kahlert C,
Res 2008;14:6302-9.
74. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Büchler MW, Weitz J, Koch M. Circulating tumour cells and
outcome in non-metastatic colorectal cancer: a prospective
Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, study. Br J Cancer 2014;112:1306-13.
Hung D, Hirmand M, Seely L, Morris MJ, Danila DC,
Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer 88. de Albuquerque A, Kubisch I, Stölzel U, Ernst D,
Foundation/Department of Defense Prostate Cancer Clinical Boese-Landgraf J, Breier G, Stamminger G, Fersis N,
Trials Consortium. Antitumour activity of MDV3100 in Kaul S. Prognostic and predictive value of circulating tumor
castration-resistant prostate cancer: a phase 1-2 study. Lancet cell analysis in colorectal cancer patients. J Transl Med
2010;375:1437-46. 2012;10:222.
75. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, 89. Allen JE, Saroya BS, Kunkel M, Dicker DT, Das A, Peters KL,
Terstappen LW. Circulating tumor cells predict survival Joudeh J, Zhu J, El-Deiry WS. Apoptotic circulating tumor
in patients with metastatic prostate cancer. Urology cells (CTCs) in the peripheral blood of metastatic colorectal
2005;65:713-8. cancer patients are associated with liver metastasis but not
76. Shaffer DR, Leversha MA, Danila DC, Lin O, CTCs. Oncotarget 2014;5:1753-60.
Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, 90. Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A,
Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Daurès JP, Maudelonde T, Fabre JM, Pantel K, Alix-Panabières
Scher HI. Circulating tumor cell analysis in patients with C. Capture of viable circulating tumor cells in the liver of
progressive castration-resistant prostate cancer. Clin Cancer colorectal cancer patients. Clin Chem 2013;59:1384-92.
Res 2007;13:2023-9. 91. Antolovic D, Galindo L, Carstens A, Rahbari N, Büchler MW,
77. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Weitz J, Koch M. Heterogeneous detection of circulating tumor
Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, cells in patients with colorectal cancer by immunomagnetic
Scher HI. Fluorescence in situ hybridization analysis of enrichment using different EpCAM-specifi c antibodies. BMC
circulating tumor cells in metastatic prostate cancer. Clin Biotechnol 2010;10:35.
Cancer Res 2009;15:2091-7. 92. Taenzer A, Alix-Panabières C, Wikman H, Pantel K.
78. Danila DC, Fleisher M, Scher HI. Circulating tumor Circulating tumor-derived biomarkers in lung cancer. J Thorac
cells as biomarkers in prostate cancer. Clin Cancer Res Dis 2012;4:448-9.
2011;17:3903-12. 93. Casavant BP, Strotman LN, Tokar JJ, Thiede SM, Traynor AM,
79. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Ferguson JS, Lang JM, Beebe DJ. Paired diagnostic and
Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, pharmacodynamic analysis of rare non-small cells lung
Fleisher M, Scher HI. Circulating tumor cell number and cancer cells enabled by the VerIFAST platform. Lab Chip
prognosis in progressive castration-resistant prostate cancer. 2014;14:99-105.
Clin Cancer Res 2007;13:7053-8. 94. Zhang MH, Chi D, Zhao S, Wang Y, Yang MP, Wang Y.
80. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Circulating tumor cells in lung cancer: Detection methods and
Carden CP, Reid AH, A’Hern R, Fong PC, Oomen NB, clinical impact. Chin German J Clin Oncol 2014;13:476-82.
Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS. 95. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG,
Circulating tumour cell (CTC) counts as intermediate Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K,
end points in castration-resistant prostate cancer (CRPC): Pepper SD, Nonaka D, Greystoke A, Kelly P, Bola B,
a single-centre experience. Ann Oncol 2009;20:27-33. Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L,
81. Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Carter L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C.
Nanus DM. Circulating tumor cells in prostate cancer Tumorigenicity and genetic profi ling of circulating tumor cells
diagnosis and monitoring: an appraisal of clinical potential. in small-cell lung cancer. Nat Med 2014;20:897-903.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦ 55